Article and Video CATEGORIES
Here is the second case in my expert round table discussion on locally advanced NSCLC with medical oncologist Dr. George Blumenschein froMD Anderson Cancer Center and radiation oncologist Dr. Walter Curran from Emory University.
We focus in this case on the decision of which patients with a Pancoast tumor should undergo surgery or a nonsurgical approach of chemo/radiation, the challenge of trying to define the right time to repeat scans after chemo/radiation in locally advanced NSCLC, and we also debate the merits of close observation vs. further interventions in the face of worrisome but still ambiguous imaging findings.
I'll add that I do find it instructive how varied the advocated treatment approaches are among the various experts when discussing not only this case but so many others I present. These are admittedly challenging cases that don't fit into any "classic" treatment approach, but these discussions of the range of alternatives offered by experts from so many places speaks to the fact that there is rarely one best strategy.
As always, here is the podcast in both audio and video formats, along with the transcript and figures.
imaging-issues-after-chemoradiation-case-blumenschein-curran-audio-podcast
imaging-issues-after-chemoradiation-case-blumenschein-curran-transcript
imaging-issues-after-chemoradiation-case-blumenschein-curran-figures
Our final case in this discussion series, which will follow shortly, is of someone who has locally advanced NSCLC on the outer reaches of what we can feasibly treat with curative intent.
This program is supported by an educational grant from OSI Pharmaceuticals. We thank them for their support.
Please feel free to offer comments and raise questions in our
discussion forums.
Forum Discussions
Hi elysianfields and welcome to Grace. I'm sorry to hear about your father's progression.
Unfortunately, lepto remains a difficult area to treat. Recently FDA approved the combo Lazertinib and Amivantamab...
Hello Janine, thank you for your reply.
Do you happen to know whether it's common practice or if it's worth taking lazertinib without amivantamab? From all the articles I've come across...
Hi elysianfields,
That's not a question we can answer. It depends on the individual's health. I've linked the study comparing intravenous vs. IV infusions of the doublet lazertinib and amivantamab...
Recent Comments
That's…